Search

Your search keyword '"Borradori, L."' showing total 748 results
Start Over Author "Borradori, L."
748 results on '"Borradori, L."'

4. 370 Role of proliferation and mechanostructural signaling in pemphigus vulgaris

Author

Rahimi, S., primary, Hariton, W.V., additional, Guo, S., additional, Sauta, P., additional, Borradori, L., additional, Hartmann, V., additional, Zare-Eelanjegh, E., additional, Paccagnan, G., additional, Zambelli, T., additional, Hundt, J.E., additional, Hammers, C.M., additional, Ludwig, R.J., additional, Busch, H., additional, and Mueller, E.J., additional

Published
2023
Full Text
View/download PDF

12. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Author

Yaylı, Savaş (ORCID 0000-0001-9402-940X & YÖK ID 151352), Borradori, L.; Van Beek, N.; Feliciani, C.; Tedbirt, B.; Antiga, E.; Bergman, R.; Boeckle, B. C.; Caproni, M.; Caux, F.; Chandran, N. S.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Didona, D.; Di Zenzo, G. M.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Goebeler, M.; Groves, R.; Guenther, C.; Horvath, B.; Hertl, M.; Hofmann, S.; Ioannides, D.; Itzlinger-Monshi, B.; Jedlickova, J.; Kowalewski, C.; Kridin, K.; Lim, Y. L.; Marinovic, B.; Marzano, A.; Mascaro, J. -M.; Meijer, J. M.; Murrell, D.; Patsatsi, K.; Pincelli, C.; Prost, C.; Rappersberger, K.; Sardy, M.; Setterfield, J.; Shahid, M.; Sprecher, E.; Tasanen, K.; Uzun, S.; Vassileva, S.; Vestergaard, K.; Vorobyev, A.; Vujic, I.; Wang, G.; Wozniak, K.; Zambruno, G.; Zillikens, D.; Schmidt, E.; Joly, P., School of Medicine, Yaylı, Savaş (ORCID 0000-0001-9402-940X & YÖK ID 151352), Borradori, L.; Van Beek, N.; Feliciani, C.; Tedbirt, B.; Antiga, E.; Bergman, R.; Boeckle, B. C.; Caproni, M.; Caux, F.; Chandran, N. S.; Cianchini, G.; Daneshpazhooh, M.; De, D.; Didona, D.; Di Zenzo, G. M.; Dmochowski, M.; Drenovska, K.; Ehrchen, J.; Goebeler, M.; Groves, R.; Guenther, C.; Horvath, B.; Hertl, M.; Hofmann, S.; Ioannides, D.; Itzlinger-Monshi, B.; Jedlickova, J.; Kowalewski, C.; Kridin, K.; Lim, Y. L.; Marinovic, B.; Marzano, A.; Mascaro, J. -M.; Meijer, J. M.; Murrell, D.; Patsatsi, K.; Pincelli, C.; Prost, C.; Rappersberger, K.; Sardy, M.; Setterfield, J.; Shahid, M.; Sprecher, E.; Tasanen, K.; Uzun, S.; Vassileva, S.; Vestergaard, K.; Vorobyev, A.; Vujic, I.; Wang, G.; Wozniak, K.; Zambruno, G.; Zillikens, D.; Schmidt, E.; Joly, P., and School of Medicine

Abstract

Background: Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or, most frequently, generalized bullous lesions. A subset of patients only develops excoriations, prurigo-like lesions, and eczematous and/or urticarial erythematous lesions. The disease, which is significantly associated with neurological disorders, has high morbidity and severely impacts the quality of life. Objectives and methodology: the Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology sought to update the guidelines for the management of BP based on new clinical information, and new evidence on diagnostic tools and interventions. The recommendations are either evidence-based or rely on expert opinion. The degree of consent among all task force members was included. Results: treatment depends on the severity of BP and patients' comorbidities. High-potency topical corticosteroids are recommended as the mainstay of treatment whenever possible. Oral prednisone at a dose of 0.5 mg/kg/day is a recommended alternative. In case of contraindications or resistance to corticosteroids, immunosuppressive therapies, such as methotrexate, azathioprine, mycophenolate mofetil or mycophenolate acid, may be recommended. The use of doxycycline and dapsone is controversial. They may be recommended, in particular, in patients with contraindications to oral corticosteroids. B-cell-depleting therapy and intravenous immunoglobulins may be considered in treatment-resistant cases. Omalizumab and dupilumab have recently shown promising results. The final version of the guideline was consented to by several patient organizations. Conclusions: the guidelines for the management of BP were updated. They summarize evidence- and expert-based recommendations useful in clinical practice., The guideline update was partly supported by the European Academy of Dermatology and Venereology (EADV) and the European Network for Rare Skin Disorders (ERN).

Published
2022

13. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)

Author

Borradori, L., primary, Van Beek, N., additional, Feliciani, C., additional, Tedbirt, B., additional, Antiga, E., additional, Bergman, R., additional, Böckle, B. C., additional, Caproni, M., additional, Caux, F., additional, Chandran, N.S., additional, Cianchini, G., additional, Daneshpazhooh, M., additional, De, D., additional, Didona, D., additional, Di Zenzo, G. M., additional, Dmochowski, M., additional, Drenovska, K., additional, Ehrchen, J., additional, Goebeler, M., additional, Groves, R., additional, Günther, C., additional, Horvath, B., additional, Hertl, M., additional, Hofmann, S., additional, Ioannides, D., additional, Itzlinger‐Monshi, B., additional, Jedličková, J., additional, Kowalewski, C., additional, Kridin, K., additional, Lim, Y. L., additional, Marinovic, B., additional, Marzano, A. V., additional, Mascaro, J.‐M., additional, Meijer, J.M., additional, Murrell, D., additional, Patsatsi, K., additional, Pincelli, C., additional, Prost, C., additional, Rappersberger, K., additional, Sárdy, M., additional, Setterfield, J., additional, Shahid, M., additional, Sprecher, E., additional, Tasanen, K., additional, Uzun, S., additional, Vassileva, S., additional, Vestergaard, K., additional, Vorobyev, A., additional, Vujic, I., additional, Wang, G., additional, Wozniak, K., additional, Yayli, S., additional, Zambruno, G., additional, Zillikens, D., additional, Schmidt, E., additional, and Joly, P., additional

Published
2022
Full Text
View/download PDF

14. Outcome and long-term treatment protocol for topical tacrolimus in oral lichen planus

Author

Utz, S, Suter, V G A, Cazzaniga, S, Borradori, L, and Feldmeyer, L

Subjects
610 Medizin und Gesundheit
Abstract

BACKGROUND AND OBJECTIVE Topical tacrolimus has been shown to be beneficial in the treatment of oral lichen planus (OLP). However, long-term effects and its optimal application protocol with gradual reduction have not been studied. Accordingly, we analysed the clinical response of OLP to tacrolimus in our daily clinical practice with a focus on the optimal long-term therapeutic scheme. METHODS Retrospective analysis of all consecutive patients diagnosed with OLP and treated with topical tacrolimus (0.03% oral rinse) in a clinical setting between 2015 and 2020. The objective clinical response was measured by a 4-point scale (complete remission, major remission, partial remission, no response), subjective impairment by a 3-point scale (severe, moderate, none). RESULTS Fifty-seven patients (74% women; median age: 66 years) were included. Fifty-six (98%) patients had prior treatment with topical steroids. After introduction of tacrolimus, objective remission (major or complete) was reached by 28%, 62%, 87% and 97% of patients after 3, 6, 12 and 24 months, respectively. Subjective remission was reported by 16%, 48%, 69% and 83% after 3, 6, 12 and 24 months of treatment, respectively. The treatment frequency could be gradually reduced from initially twice daily to once daily or less in 28%, 61%, 78% and 87% after 3, 6, 12 and 24 months, respectively. 41% of patients completely suspended the treatment at one point, but 67% of them experienced a relapse after a median time of 3.3 months. Four patients (7%) developped a squamous cell carcinoma (SCC) during the observation period. Otherwise, there were only few and minor side-effects. CONCLUSION Topical tacrolimus can be an effective second-line therapy for OLP refractory to potent topical corticosteroids. The therapy frequency can often be reduced during the maintenance period. Both signs of clinical activity and subjective impairment should guide therapy. Regular follow-up is necessary to recognize possible SCC.

Published
2022
Full Text
View/download PDF

20. Diagnostic delay in hidradenitis suppurativa is a global problem

Author

Saunte, D. M., Boer, J., Stratigos, A., Szepietowski, J. C., Hamzavi, I., Kim, K. H., Zarchi, K., Antoniou, C., Matusiak, L., Lim, H. W., Williams, M., Kwon, H. H., Gurer, M. A., Mammadova, F., Kaminsky, A., Prens, E., van der Zee, H. H., Bettoli, V., Zauli, S., Hafner, J., Lauchli, S., French, L. E., Riad, H., El-Domyati, M., Abdel-Wahab, H., Kirby, B., Kelly, G., Calderon, P., del Marmol, V., Benhadou, F., Revuz, J., Zouboulis, C. C., Karagiannidis, I., Sartorius, K., Hagstromer, L., McMeniman, E., Ong, N., Dolenc-Voljc, M., Mokos, Z. B., Borradori, L., Hunger, R. E., Sladden, C., Scheinfeld, N., Moftah, N., Emtestam, L., Lapins, J., Doss, N., Kurokawa, I., and Jemec, G. B.E.

Published
2015
Full Text
View/download PDF

30. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I

Author

Rashid, H., primary, Lamberts, A., additional, Borradori, L., additional, Alberti‐Violetti, S., additional, Barry, R.J., additional, Caproni, M., additional, Carey, B., additional, Carrozzo, M., additional, Caux, F., additional, Cianchini, G., additional, Corrà, A., additional, Diercks, G.F.H., additional, Dikkers, F.G., additional, Di Zenzo, G., additional, Feliciani, C., additional, Geerling, G., additional, Genovese, G., additional, Hertl, M., additional, Joly, P., additional, Marzano, A.V., additional, Meijer, J.M., additional, Mercadante, V., additional, Murrell, D.F., additional, Ormond, M., additional, Pas, H.H., additional, Patsatsi, A., additional, Prost, C., additional, Rauz, S., additional, van Rhijn, B.D., additional, Roth, M., additional, Schmidt, E., additional, Setterfield, J., additional, Zambruno, G., additional, Zillikens, D., additional, and Horváth, B., additional

Published
2021
Full Text
View/download PDF

42. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)

Author

Joly, P., primary, Horvath, B., additional, Patsatsi, Α, additional, Uzun, S., additional, Bech, R., additional, Beissert, S., additional, Bergman, R., additional, Bernard, P., additional, Borradori, L., additional, Caproni, M., additional, Caux, F., additional, Cianchini, G., additional, Daneshpazhooh, M., additional, De, D, additional, Dmochowski, M., additional, Drenovska, K., additional, Ehrchen, J., additional, Feliciani, C., additional, Goebeler, M., additional, Groves, R., additional, Guenther, C., additional, Hofmann, S., additional, Ioannides, D., additional, Kowalewski, C., additional, Ludwig, R., additional, Lim, Y.L., additional, Marinovic, B., additional, Marzano, A.V., additional, Mascaró, J.M., additional, Mimouni, D., additional, Murrell, D.F., additional, Pincelli, C., additional, Squarcioni, C.P., additional, Sárdy, M., additional, Setterfield, J., additional, Sprecher, E., additional, Vassileva, S., additional, Wozniak, K., additional, Yayli, S., additional, Zambruno, G., additional, Zillikens, D., additional, Hertl, M., additional, and Schmidt, E., additional

Published
2020
Full Text
View/download PDF

43. The evolving field of Dermato‐oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force

Author

Garbe, C., primary, Peris, K., additional, Soura, E., additional, Forsea, A.M., additional, Hauschild, A., additional, Arenbergerova, M., additional, Bylaite, M., additional, Marmol, V., additional, Bataille, V., additional, Samimi, M., additional, Gandini, S., additional, Saiag, P., additional, Eigentler, T.K., additional, Lallas, A., additional, Zalaudek, I., additional, Lebbe, C., additional, Grob, J.‐J., additional, Hoeller, C., additional, Robert, C., additional, Dréno, B., additional, Arenberger, P., additional, Kandolf‐Sekulovic, L., additional, Kaufmann, R., additional, Malvehy, J., additional, Puig, S., additional, Leiter, U., additional, Ribero, S., additional, Papadavid, E., additional, Quaglino, P., additional, Bagot, M., additional, John, S.M., additional, Richard, M.‐A., additional, Trakatelli, M., additional, Salavastru, C., additional, Borradori, L., additional, Marinovic, B., additional, Enk, A., additional, Pincelli, C., additional, Ioannides, D., additional, Paul, C., additional, and Stratigos, A.J., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results